Clindacyl tablets-Hyperdrug

Presentation Three tablet strengths are available: Clindacyl 25mg containing 25mg Clindamycin (as Clindamycin Hydrochloride) Clindacyl 75mg containing 75mg Clindamycin (as Clindamycin Hydrochloride) Clindacyl 150mg containing 150mg Clindamycin (as Clindamycin Hydrochloride) Uses Clindacyl Tablets are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, Fusobacterium necrophorum, Clostridium perfringens and osteomyelitis caused by Staphylococcus aureus in dogs. Clindacyl Tablets can also be used to help provide antimicrobial cover during dental procedures.

Dosage and administration For oral administration. For treatment of infected wounds, abscesses, oral cavity/dental infections, administer 5.5 mg/kg bodyweight every 12 hours for 7 - 10 days.

Treatment may be extended to a maximum of 28 days based on clinical judgement. If no improvement is seen within 4 days, the sensitivity of the pathogens involved should be redetermined. For the treatment of superficial pyoderma administer 11 mg/kg every 24 hours.

Continue treatment for at least 21 days. For the treatment of osteomyelitis administer 11 mg/kg every 12 hours for at least 28 days.

If no improvement is seen within 14 days, the sensitivity of the pathogens involved should be redetermined. To help provide antimicrobial cover during dental procedures, a 10 day course of 5.5 mg/kg every 12 hours is recommended beginning 5 days before the intended procedure and continuing for 5 days thereafter).

Contra-indications, warnings, etc Withdrawal periods Not applicable Do not administer to animals with hypersensitivity to clindamycin and lincomycin preparations. Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants. Clindamycin sometimes causes the overgrowth of non sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures should be taken according to the clinical situation. Vomiting and diarrhoea are observed occasionally. During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy. Neuromuscular blocking effects have been observed with clindamycin possibly leading to an increase of efficacy of other neuromuscular blocking agents. The concomitant use of such drugs must be handled with care. Clindamycin should not be used concomitantly with chloramphenicol or macrolides because they may antagonise each other at the site of action. Symptoms of overdose include vomiting, inappetency and diarrhoea. In such cases, treatment should be stopped immediately and the dogs treated symptomatically. Before use of Clindacyl tablets, the identification of causative pathogenic micro-organisms should be carried out and their susceptibility to clindamycin should be established. Clindamycin and lincomycin show parallel-resistance. There is a partial cross-resistance to erythromycin and other macrolide-antibiotics. While high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches or breeding male dogs has not been established. Operator warning None Pharmaceutical precautions No special storage precautions are necessary. Dispose of any unused product or container in accordance with any guidance from an appropriate waste regulation authority. Any product remaining with the end user should be returned to the veterinary surgeon.

Legal category POM-v (previously POM). Packaging Quantities Polyethylene bottle with child resistant tamper evident snap-cap closures containing 100 tablets. Further information Clindamycin, a chlorinated analogue of lincomycin, is an antibiotic with bacteriostatic action. Bactericidal actions have also been reported. Clindamycin is rapidly absorbed; following oral administration up to 90% of the active ingredient is absorbed from the gastro-intestinal tract. Bioavailability is greater in fasting dogs than fed dogs. Clindamycin crosses the placental barrier and can be detected in milk. Marketing authorisation no Clindacyl 25mg VM 08007/4104 Clindacyl 75mg VM 08007/4087 Clindacyl 150mg VM 08007/4103